tert-butyl (4-((2-((2-(((4bS,8R,8aS,14bR)-7-(cyclopropylmethyl)-1,8a-dihydroxy-5,6,7,8,8a,9,14,14b-octahydro-4,8-methanobenzofuro[2,3-a]pyrido[4,3-b]carbazol-13-yl)amino)-2-oxoethyl)amino)-2-oxoethyl)amino)-4-oxobutanoyl)glycylglycinate | 804483-35-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (4-((2-((2-(((4bS,8R,8aS,14bR)-7-(cyclopropylmethyl)-1,8a-dihydroxy-5,6,7,8,8a,9,14,14b-octahydro-4,8-methanobenzofuro[2,3-a]pyrido[4,3-b]carbazol-13-yl)amino)-2-oxoethyl)amino)-2-oxoethyl)amino)-4-oxobutanoyl)glycylglycinate
• CAS: 804483-35-0
• 化学式: C₄₂H₅₁N₇O₁₀
• 分子量: 813.908
• InChiKey: XPHFLWFHNBJMHB-GMYCILDFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  59.0
• 可旋转键数：
  14.0
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  240.52
• 氢给体数：
  8.0
• 氢受体数：
  11.0

反应信息

• 作为反应物：
  描述：

  tert-butyl (4-((2-((2-(((4bS,8R,8aS,14bR)-7-(cyclopropylmethyl)-1,8a-dihydroxy-5,6,7,8,8a,9,14,14b-octahydro-4,8-methanobenzofuro[2,3-a]pyrido[4,3-b]carbazol-13-yl)amino)-2-oxoethyl)amino)-2-oxoethyl)amino)-4-oxobutanoyl)glycylglycinate 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 反应 24.0h， 以70%的产率得到(4-((2-((2-(((4bS,8R,8aS,14bR)-7-(cyclopropylmethyl)-1,8a-dihydroxy-5,6,7,8,8a,9,14,14b-octahydro-4,8-methanobenzofuro[2,3-a]pyrido[4,3-b]carbazol-13-yl)amino)-2-oxoethyl)amino)-2-oxoethyl)amino)-4-oxobutanoyl)glycylglycine
  参考文献：
  名称：

  A Bivalent Ligand (KDN-21) Reveals Spinal δ and κ Opioid Receptors Are Organized as Heterodimers That Give Rise to δ₁ and κ₂ Phenotypes. Selective Targeting of δ−κ Heterodimers

  摘要：

  In view of recent pharmacological studies suggesting the existence of delta-kappa opioid receptor heterodimers/oligomers in the spinal cord, we have synthesized and evaluated (intrathecally in mice) a series of bivalent ligands (KDN series) containing kappa and delta antagonist pharmacophores. Pharmacological and binding data have provided evidence for the bridging of spinal delta-kappa receptor heterodimers by KDN-21 and for their identification as delta(1) and kappa(2). The selectivity profile of KDN-21 and the apparent absence of coupled delta(1)-kappa(2) phenotypes in the brain suggest a new approach for targeting receptors.

  DOI：

  10.1021/jm0342358
• 作为产物：
  描述：

  N-[(tert-Butoxycarbonylmethyl-carbamoyl)-methyl]-succinamic acid 在 palladium on activated charcoal 氢气 、 1-羟基苯并三唑 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、482.63 kPa 条件下， 反应 120.5h， 生成 tert-butyl (4-((2-((2-(((4bS,8R,8aS,14bR)-7-(cyclopropylmethyl)-1,8a-dihydroxy-5,6,7,8,8a,9,14,14b-octahydro-4,8-methanobenzofuro[2,3-a]pyrido[4,3-b]carbazol-13-yl)amino)-2-oxoethyl)amino)-2-oxoethyl)amino)-4-oxobutanoyl)glycylglycinate
  参考文献：
  名称：

  A Bivalent Ligand (KDN-21) Reveals Spinal δ and κ Opioid Receptors Are Organized as Heterodimers That Give Rise to δ₁ and κ₂ Phenotypes. Selective Targeting of δ−κ Heterodimers

  摘要：

  In view of recent pharmacological studies suggesting the existence of delta-kappa opioid receptor heterodimers/oligomers in the spinal cord, we have synthesized and evaluated (intrathecally in mice) a series of bivalent ligands (KDN series) containing kappa and delta antagonist pharmacophores. Pharmacological and binding data have provided evidence for the bridging of spinal delta-kappa receptor heterodimers by KDN-21 and for their identification as delta(1) and kappa(2). The selectivity profile of KDN-21 and the apparent absence of coupled delta(1)-kappa(2) phenotypes in the brain suggest a new approach for targeting receptors.

  DOI：

  10.1021/jm0342358